The Promising Anti CD47 Drugs Market fueled by Rising Cancer Prevalence
The anti CD47 drugs market has emerged as a promising avenue for cancer treatment. Anti CD47 drugs work by blocking the CD47 protein found on tumor cells, thereby allowing macrophages to identify and eliminate cancer cells. These drugsoffer significant advantages over traditional chemotherapy by precisely targeting cancer cells while sparing healthy cells from collateral damage.
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.
.As the fourth leading cause of death worldwide, cancer prevalence continues to rise with aging populations and changing lifestyle habits. Despite advances, current therapies often fail to provide durable responses or come with toxicity issues. Anti CD47 drugs present a targeted approach and have shown encouraging results in clinical trials for difficult-to-treat cancers like leukemia, lymphoma and solid tumors.
Key players operating in the anti CD47 drugs market are Magrolimab by Five Prime Therapeutics, ALX148 by ALX Oncology, VIR-2218 by VIR Biotechnology.
The growing cancer burden along with limitations of existing treatment options is fueling demand for novel targeted therapies like Anti CD47 Drugs Market . Their ability to enhance innate antitumor immunity while minimizing off-target effects makes them an attractive alternative.
Get more insights on – Anti CD47 Drugs Market
Get this Report in Japanese Language: 抗CD47薬市場
Get this Report in Korean Language: 항 CD47 약물 시장
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian